Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than financial performance results.
Material Changes
The filing reports an increase in American Depositary Receipts (ADRs) held by administrators of the SmithKline Beecham Mid-Term Incentive Plan. This increase resulted from the re-investment of the dividend paid to shareholders on July 7, 2011. The transaction price was $43.91 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It is a regulatory disclosure of a specific transaction under Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 12, 2011.
- Transaction Type: Increase in ADR holdings via dividend re-investment.
- Price per ADR: $43.91.
- Specific Holder: Mr. E J Gray (16,428 ADRs).
- Dividend Date: July 7, 2011.